

Section 2: Insurance Information

PATIENT ENROLLMENT SECTION Olumiant® (baricitinib) Rheumatology

OFFICE: Complete the entire form and submit pages 1-4 to Olumiant Together™ via fax at 1-844-658-4268 or upload online at https://patientsupportnow.org and code: 8446584268. For assistance, call 1-844-OLUMIANT (1-844-658-6426), Monday-Friday 8am - 10pm ET.

PP-RC-US-2210 03/2024 @Lilly USA, LLC 2024. All rights reserved.

PUBLISHED 03/2024

Patient Name (First, MI, Last)		DOB (MM/DD/YYYY)					
Address	City	State	Zip				
US or Puerto Rico Resident ☐ Yes ☐ No	Gender ☐ M ☐ F Prefer	red Language 🗌 English 🔲 Spanis	sh Other				
Phone*							
*By checking the box, I agree to receive automated marketing calls and texts from and on behalf of Eli Lilly and Company. I understand that I am not required to provide my number as a condition of receiving goods and services. Message and data rates may apply.							
By checking the box, I agree to be contacted to: provide feedback on my experience with the related products, services, and programs; to share my story; and, to participate in market and medical research studies about products and services.							
Must select one of the following: \(\square\) No Insurance C	Coverage Copy of Policyholder's In	surance Card (Front and Back) Is At	tached Provide Information Below				
Primary Prescription Insurance Company							
Insurance Company Phone #	Ca	rdholder Name					
Policy/ID	Gr	oup #					
RX BIN	PC	;N					
Please select if you would like to enroll by checking the corresponding checkbox below. By enrolling in the service below, you are agreeing to the Terms of Participation and consenting to the collection of your information, inclusive of health information as described under the Privacy Notice on page 5.							
1. Olumiant® Savings Card							
SAVINGS CARD ELIGIBILITY (must co	nfirm the below statements in orde	r to be eligible)					
I confirm that I am a resident of the U	nited States or Puerto Rico who is	18 years of age					
☐ I confirm that I am NOT enrolled in a g Part D, Medigap, DoD, VA, TRICARE®/		S , S,					

TERMS OF PARTICIPATION AND PROGRAM DISCLOSURES:

Your healthcare provider has talked with you about using Olumiant®, an Eli Lilly and Company medicine. Olumiant Together™ offers personalized support to Patients at no charge and was created to help you have a positive experience as you get started with and use this medicine. By checking the corresponding optional boxes above, you consent to your enrollment into Olumiant Together™. As part of your participation in Olumiant Together™, you understand and authorize Lilly USA, LLC to retain and use your personal information for the purposes described in this form. Eli Lilly and Company, Lilly USA, LLC and its affiliates, agents, representatives, and service providers (together "Lilly") may use, disclose, and/or transfer the personal information you supply to provide services related to your condition and treatment to administer the program. The Olumiant TogetherTM Support team can contact you by email, mail or telephone to provide personalized services and information and materials directly related to your condition and therapy; responding to customer service requests and/or questions about your treatment; disclosing your enrollments and use of these services to your doctors and insurers; analyzing and/or measuring program performance and program effectiveness for future enhancements; and other activities related to your condition and therapy that are part of Olumiant Together. Your personal information, including information that may be related to your health, is needed to fulfill your request. To cancel your participation in the program, please contact us at 1-844-OLUMIANT (1-844-658-6426) Mon-Fri, 8am -10pm ET. For information about Lilly's privacy practices, please see our Privacy Statement at https://privacynotice.lilly.com.







PP-RC-US-2210 03/2024 ©Lilly USA, LLC 2024. All rights reserved.

PUBLISHED 03/2024

OFFICE: Complete the entire form and submit pages 1-4 to Olumiant Together™ via fax at 1-844-658-4268 or upload online at https://patientsupportnow.org and code: 8446584268. For assistance, call 1-844-OLUMIANT (1-844-658-6426), Monday-Friday 8am - 10pm ET.

By enrolling in the Olumiant Savings Card Program ("Program") and using the Olumiant Savings Card ("Card"), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Card Eligibility:

- You have been prescribed Olumiant® (baricitinib) consistent with FDA-approved product labeling
- You are enrolled in a commercial drug insurance plan
- You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation. Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program.
- You are a resident of the United States or Puerto Rico
- You are 18 years of age or older

Card Terms and Conditions:

For patients with commercial drug insurance coverage for Olumiant: You must have commercial drug insurance that covers Olumiant and a prescription consistent with FDA-approved product labeling to pay as little as \$5 for a 1-month prescription fill of Olumiant. Month is defined as 30-days. Card must be first used by no later than 12/31/2024. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum annual savings of up to \$9,450 per calendar year. Card may be used for up to a maximum of 13 prescription fills per calendar year and up to a maximum of 24 prescription fills over the lifetime of the Program, subject to the previously stated maximum monthly and annual savings limit. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly USA, LLC's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2026 or 24 months after you first use the Card, whichever comes first.

For patients with commercial drug insurance who do not have coverage for Olumiant: You must have commercial drug insurance that does not cover Olumiant and a prescription consistent with FDA-approved product labeling to pay as little as \$25 for a 1-month supply of Olumiant. Month is defined as 30-days. Card must be first used by no later than 12/31/2024. Card savings are subject to a maximum monthly savings and a separate maximum annual savings. Card may be used for up to a maximum of 13 prescription fills per year and up to a maximum 24 prescription fills over the lifetime of the Program, subject to the maximum monthly and annual savings limit. Card must be first used by no later than 12/31/2024. Participation in the Program requires submission of a prior authorization (PA) prior to the first prescription fill. If coverage is denied, an appeal must be submitted prior to 5th month prescription fill. To remain eligible for the Program, a new PA, appeal, or medical exception must be submitted prior to the 13th prescription fill and as required by Lilly at its sole discretion. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. Subject to Lilly USA, LLC's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions, which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2026 or 24 months after you first use the Card, whichever comes first.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program ("AFP") (examples include, but are not limited to, ImpaxRX, Payer Matrix, SHARx, Script Sourcing, and Paydhealth) that requires you to apply to the Olumiant Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Olumiant, you are not eligible for and are prohibited from using the Olumiant Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Olumiant Savings Card Program. You agree to inform Olumiant Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Olumiant limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Olumiant, only allows partial coverage for Olumiant, removes coverage for Olumiant and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Olumiant, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Olumiant. Card savings are not valid for: Massachusetts residents if an AB-rated generic dequivalent is additional cardiological payments. therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Olumiant Savings Card and agree to call the Olumiant Savings Card Program at 1-844-658-6426 to stop participation. Card activation is required. No party may seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Olumiant. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. The Card is not insurance. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Eligibility criteria, and terms and conditions for the Olumiant Savings Card Program may change from time to time; the most current version can be found at https://www.Olumiant.com. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/o therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you 12/31/2026 or 24 months after you first use the Card, whichever comes first.







PATIENT HIPAA AUTHORIZATION

OFFICE: Complete the entire form and submit pages 1-4 to
Olumiant Together™ via fax at 1-844-658-4268 or upload online at
https://patientsupportnow.org and code: 8446584268.
For assistance, call 1-844-OLUMIANT (1-844-658-6426),
Monday-Friday 8am − 10pm ET.

PP-RC-US-2210 03/2024 @Lilly USA, LLC 2024. All rights reserved.

PUBLISHED 03/2024

Before Olumiant Together[™] can start helping you, Lilly may ask for some information about you and your health from your Health Care Entities (as defined below). This is known as your Protected Health Information, or PHI. By signing this form, you understand and agree that your PHI may be shared with or used by Lilly as explained below.

PHI includes information like:

- Your health insurance or benefits, including how much coverage you have
- All records about your treatment
- Whether you're staying on your medicine or treatment

If you agree, your PHI may be shared by these entities (together "Health Care Entities"):

- Your doctors and other healthcare providers
- Your healthcare plan or health insurance company
- Clearinghouses or other agents
- Your pharmacy
- Others who might have your PHI on behalf of your healthcare providers, pharmacies and healthcare plans

Your PHI is used in ways like these:

- To learn how much of your Lilly treatment is covered by your insurance
- To help you find other ways to afford your treatment
- To track your use of your Lilly treatment
- To share information with your healthcare provider
- To make sure that you receive high-quality services from the program
- To measure program performance and make program improvements
- Internal Lilly use of data to drive business decisions and metrics on hub performance
- Reports to our sales force regarding HCP use of hub services
- Conversations/messages to your HCP regarding trends and hub performance

Other things you should know about sharing and using your PHI:

- We only ask for and share the PHI that we need to provide the benefits you want. We do not ask for any PHI that we do not need, but we may receive some in the health records sent to us. Your PHI will be released to Eli Lilly and Company and Lilly USA, LLC and its affiliates, agents, representatives, and service providers (together "Lilly").
- You don't have to give permission to share your PHI with Lilly to receive treatment from your healthcare providers, your prescription from your pharmacy, or benefits from your healthcare plan, but Olumiant Together™ may not be able to help you without it
- After your PHI has been shared, it may no longer be covered by federal and state privacy laws (such as HIPAA), and it may be shared again with others by Lilly
- Your signed permission to share and use your PHI lasts for 3 years from the date of your signature unless you are a resident of Maryland,
 Maine, or Montana, in which case the permission will last for 1 year from the date of your signature. In either case, you may revoke your permission before then by writing to PO Box 221349, Charlotte, NC 28222, which will preclude reliance on the authorization after the date your written revocation is received
- Your healthcare providers (such as pharmacies) may be paid by us in exchange for sharing your PHI. They may also be paid by us to use your PHI to provide services, such as contacting you about Lilly products
- You can stop sharing your PHI with us or change what you share by calling us at 1-844-OLUMIANT (1-844-658-6426) or by writing us at PO Box 221349, Charlotte, NC 28222
- Your cancellation or revocation of this Authorization will be effective when your Health Care Entities receive notice of your
 cancellation or revocation, and will not apply to any information shared with Lilly by your Health Care Entities prior to the time
 those Health Care Entities receive notice

By signing this form, I attest that I have read and agree to the Patient HIPAA Authorization. I understand I am entitled to a copy of this signed Authorization.



Signature of Patient	Date Signed (MM/DD/YYYY)
Printed Name of Patient	DOB (MM/DD/YYYY)
Not signing this form will result in an incomplete submission and a delay in requested services	





PRESCRIBER ENROLLMENT SECTION Olumiant® (baricitinib) Rheumatology

PP-RC-US-2210 03/2024 @Lilly USA, LLC 2024. All rights reserved.

PUBLISHED 03/2024

OFFICE: Complete the entire form and submit pages 1-4 to
Olumiant Together™ via fax at 1-844-658-4268 or upload online at
https://patientsupportnow.org and code: 8446584268.
For assistance, call 1-844-OLUMIANT (1-844-658-6426),
Monday-Friday 8am − 10pm ET.

Section 4: Prescriber information

Section 5: Diagnosis

HCP Service Selection & Prescription

Name (First, Las	st)	NPI #						
Practice Name		Phone	Fax _					
Address		City	State	Zip _				
Office Contact I	Office Contact Name Office Contact Phone							
Office Contact Email								
Collaborating P	hysician	NPI #	Group Tax ID					
Patient Name (First, MI, Last) DOB (MM/DD/YYYYY)								
Address		City	State	Zip				
Diagnosis: Rheumatoid Arthritis with Rheumatoid Factor, unspecified (ICD-10 Code: M05.9) Other ICD-10 Code:								
Benefits Investigation Support (select one choice)								
Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent— Specialty Pharmacy Phone Number Lilly Conducted Benefits Investigation—Olumiant Together™ will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowest out-of-pocket cost available for Olumiant® and will forward the prescription to the Specialty Pharmacy that the Patient selects. An Olumiant Together™ representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW.								
Olumiant® Rheumatology Prescription — Fill out corresponding prescription below and sign at the bottom of the page								
\rightarrow	☐ Patient has had an inadequate response to one or more TNF antagonist therapies (must verify for FDA-Approved use)							
	Diagnosis	Olumiant® Prescribing Information (PI) Dosing	Quantity	Days Supply	Refills			
You must select the Inadequate Response and Dosing	Rheumatoid Arthritis with Rheumatoid Factor, unspecified	Olumiant® 2 mg tablet, once daily by mouth	30	30				
		Olumiant® 1 mg tablet, once daily by mouth for Patients with moderate renal impairment or who are taking strong OAT3 inhibitors	30	30				
Prior RA Treatment (select all that apply) □ Methotrexate □ HUMIRA® □ ENBREL® □ REMICADE® □ CIMZIA® □ SIMPONI® □ XELJANZ® □ RINVOQ™								
□ ORENCIA®	□ ACTEMRA® □	KEVZARA® ☐ Kineret® ☐ Other(s)						
By signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly USA, LLC, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has directed my disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the duration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form, the prescription complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharmacy. I understand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Olumiant® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRIBER MUST MANUALLY SIGN AND DATE. Rubber stamps, signature by other office personnel for the Prescriber, and computer-generated signatures will not be accepted.								
Dispense as written Not signing this form will result in an incomplete submission and a delay in requested services May substitute/brand exchange permitted Date Signed (MM/DD/YYYY) Date Signed (MM/DD/YYYY)								





PP-RC-US-2210 03/2024 ©Lilly USA, LLC 2024. All rights reserved.

PUBLISHED 03/2024

Privacy Notice:

This Privacy Notice ("Notice") is intended to supplement the Eli Lilly and Company Privacy Statement (https://privacynotice.lilly.com) and the Consumer Health Privacy Notice (https://www.lillyhub.com/legal/lillyusa/CHPN.html) that can be accessed in the footers of Lilly's websites. This Notice is to provide you with information about the personal information, including health information, we may collect, use, disclose or otherwise process, and your rights and choices with respect to your information.

The categories of health information we collect will depend on how you interact with Lilly Services and the information you choose to provide. We may collect:

- Health conditions, treatments, diseases, or diagnosis
- Social, psychological, behavioral, and medical interventions
- Health-related surgeries or procedures
- Use or purchase of prescribed medication
- Bodily functions, vital signs, symptoms, or measurements of other types of consumer health data
- Diagnoses or diagnostic testing, treatment, or medication

- Reproductive or sexual health information
- Biometric data
- Genetic data
- Data that identifies a consumer seeking health care services
- Other information that may be used to infer or derive data related to the above or other health information.

With your consent, we may use the health information we collect for the following purposes, as further described in our privacy statements:

- Providing Services and support.
- Analytics and improvement.
- Customization and personalization.
- Marketing and advertising.

- Security and protection of rights.
- · Legal proceedings and obligations.
- General business and operational support.

Lilly does not sell or share your health information with third parties without your consent or authorization. We may disclose health information to our processors for our business purposes or at your direction to provide you with products and Services that you request.

We may use and save your personal information to meet legal or regulatory obligations that are in the legitimate interest of Lilly, to fulfill legitimate and lawful business purposes in accordance with Lilly's record retention policies and applicable laws and regulations, and to respond to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Some of this personal information may be considered sensitive under applicable laws, such as information about your health or medical diagnosis and demographic information collected in some circumstances, such as race, ethnic origin, and sexual orientation. We may process your sensitive PI with your consent, or as otherwise permitted by law.

Upon verification, you have rights with respect to the collection, use and storage of your information. These rights may include access to your information and how it is being used or shared, the right to correct, delete or limit use of your information or to withdraw consent for us to collect and use your information. There may be certain exceptions and limitations that apply to your request including the right to have your information transmitted to another entity or person in a machine-readable format. To exercise your rights, you or your authorized representative may submit a request to datarights@lilly.com or 1-800-Lilly-Rx (1-800-545-5979). You will not be discriminated against for exercising any of your rights. You may be entitled, in accordance with applicable law, to appeal a refusal to take action on your request. To do so, please contact us by using one of the methods listed here or in How to Contact Us section of the online Privacy Statement.

If you wish to raise a complaint on how we have handled your personal information, you can contact the Global Privacy Office and Data Protection Officer at privacy@lilly.com, who will investigate the matter. If you are not satisfied with our response or have any concerns about how your data is being processed, you can register a complaint with a relevant regulatory authority (e.g., a Data Protection Authority (DPA) or Attorney General).

